

## Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. *Lancet Infect Dis* 2011; published online Dec 13. DOI:10.1016/S1473-3099(11)70339-5.

**Supplementary Table:**

**Table 1**

**Characteristics of women included and excluded from the analysis (n=48,426)**

Characteristic	Included N=17,613	Excluded N=30,813
Age, yrs, mean $\pm$ SD, [range]	27 $\pm$ 7 (21-32) [13-52]	26 $\pm$ 7 (20-30) [13-50]
Teenager < 20 y.o., n (%)	2605/17,612 (14.8)	4245/30,704 (17.1)
Gravidity, median (IQ range) [range]	3 (2-5) [1-17]	3 (1-4) [1-19]
Parity, median (IQ range) [range]	2 (1-3) [0-13]	2 (0-3) [0-17]
Primigravidae, n (%)	3,626/17,585 (20.6)	8,352/30,615 (27.3)
Smokers, n (%)	4320/14,390 (30.0)	6,435/20,512(31.4)

IQ range – inter-quartile range; SD - standard deviation.

Missing data: Age and teenager n=110, primigravidae n=226, parity n=226, gravidity n=244, smoking n=13,524 .

**Table 2**

**Characteristics of women with known and unknown outcomes of pregnancy presenting in the first trimester (with no malaria or a single first trimester episode of malaria).**

Characteristic	Unknown outcome N=2,376	Known outcome N=17,613	P-value
Age, yrs, mean $\pm$ SD, [range]	26 $\pm$ 7 [13-46]	27 $\pm$ 7 [13-52]	<0.001
Teenager < 20 y.o., n (%)	434/2,376 (18.3)	2605/17,612 (14.8)	<0.001
Gravidity, median (IQ range) [range]	2 (1-4) [1-16]	3 (2-5) [1-17]	<0.001
Parity, median (IQ range) [range]	1 (0-3) [0-13]	2 (1-3) [0-13]	<0.001
Primigravidae, n (%)	738/2,376 (31.1)	3,626/17,585 (20.6)	<0.001
Smokers, n (%)	619/2,270 (27.3)	4,320/14,390 (30.0)	0.008
Malaria 1 <sup>st</sup> trimester, n (%)	363/2,376 (15.3)	945/17,613 (5.4)	<0.001
Signs of pregnancy loss at presentation, n (%)	219/2,370 (8.9)	1196/17,613 (6.8)	<0.001
<b>Antimalarial Treatment</b>			
Chloroquine	153/363 (42.1)	429/945 (45.4)	0.025
Quinine	168/363 (46.3)	390/945 (41.3)	
Artesunate	36/363 (9.9)	92/945 (9.7)	
Mefloquine	3/363 (0.3)	32/945 (3.4)	
Other	3/363 (0.8)	2/945 (0.2)	

SD-standard deviation; IQ range-inter-quartile range;

Missing data: Teenager n=1, primigravidae n=28, parity n=37, gravidity n=28, smoking n=3329, signs of pregnancy loss at first consultation n= 6.

**Table 3.**  
**Congenital abnormalities in the first trimester, single treatments.**

<b>Treatment</b>	<b>Age yrs</b>	<b>Gravidity (G) Parity (P)</b>	<b>EGA malaria treatment, wks</b>	<b>Abnormality</b>	<b>Critical period of organ formation</b>	<b>Proportion of abnormality in women treated with antimalarial</b>	<b>Proportion of same abnormality in women with no antimalarial treatment</b>
Artesunate	33	G7 P4	12.5	Syndactyly foot - digits fused bilateral 2, 3 and 4 no toe nails	Toe nails week 14	2.3 (1/44)	2.5 (5/198)
Artesunate	21	G1 P0	3.9	Hydrocephalus	Brain 3-16 wks	2.3 (1/44)	3.0 (6/198)
Quinine	20	G2 P1	9.7	Cleft lip and palate	Palate- 6-8 wks	0.4 (1/258)	12.6 (25/198)
Chloroquine	25	G3 P2	13	Arthrogyriposis	Limb rotation 8 wks	0.4 (1/260)	1.0 (2/198)

EGA – estimated gestational age.